Teva wins docs to bolster case that Boehringer’s Spiriva patents were obvious
Healthcare 2019-05-07 11:16 pm By Christine Caulfield | Melbourne
Please login to bookmark Close

Israeli drug maker Teva has won its bid for communications between Germany-based Boehringer and capsule manufacturers to help prove its claim that a patent at the centre of a dispute over the top-selling inhaler Spiriva was invalid for obviousness.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au